Exploring the Emerging Treatment Landscape of Relapsed/Refractory Diffuse Large B-Cell | PTCE Pharmacy Connect
Description
Educational Objective:
- Outline various challenges and uncertainties affecting the optimization of treatment with novel immunotherapeutic modalities for relapsed/refractory diffuse large B-cell lymphoma.
Faculty:
Victoria Nachar, PharmD, BCOP
Clinical Pharmacist Specialist - Hematology
University of Michigan Rogel Cancer Center
Ann Arbor, Michigan
Moderator:
Laura R. Bobolts, PharmD, BCOP
SVP, Clinical Strategy and Growth
OncoHealth
Plantation, Florida
Victoria Nachar, PharmD, BCOP & Laura R. Bobolts, PharmD, BCOP, have no financial relationships with commercial interests to disclose.
Pharmacy Times Continuing Education™ is accredited by the Accreditation Council for Pharmacy Education (ACPE) as a provider of continuing pharmacy education. This activity is approved for 0.5 contact hours (0.05 CEU) under the ACPE universal activity number 0290-0000-22-611-H01-P. The activity is available for CE credit through December 22, 2023.
This activity is supported by independent medical education grants from Regeneron Pharmaceuticals, Inc; Genmab; and AbbVie, Inc.
United States
